Vivendy Therapeutics Company

Vivendy Therapeutics is a pharmaceutical company founded in 2006 that focuses on developing enzyme replacement therapy for the treatment of Morbus Morquio (MPS IVA), a rare lysosomal storage disease. They have developed a modified recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that improves enzyme activity and enhances the efficacy of the therapy significantly.



Headquarters: Basel, Basel-Stadt, Switzerland
Technology: Prevention
Funding Status: Early Stage Venture
Employee Number: 1-10
Investment Stage: N/A
Number Of Exists: N/A
Investor Type: N/A
Founded Date: 2006
Industry: Regenerative medicine
Estimated Revenue: approximately €9.0